The August edition of the newsletter contains
- > Finance funding and industry news including a round-up of recent events in the Duchenne Muscular Dystrophy market, Ipsen completing the purchase of UK based biotech Syntaxin and Audentes Therapeutics raising $30m in venture financing.
- > A special feature profiling the BioValley Biotechnology cluster. The cluster is unique in many respects including that it spans across three countries
- > Part II of Michael O’Neill, Founder and R&D Director of Inflection Bioscience, article looking at managing conflict in biotech organisations
- > An article by Liftstream CEO, Karl Simpson looking at the role professionals from a big pharma can play in start-up companies.
- > A summary of Liftstream news including our attendance at a number of industry conferences in the coming months
To read this month’s newsletter please click here
To sign up to our monthly newsletter please click here
